For & Against

Claude View

What's Next

Four dated events over the next eight weeks decide whether the FY26 recovery narrative is a genuine re-rating or a cost-pull head-fake. The May 2026 Q4 print is the hinge — not because the top-line is in doubt (9M FY26 already beats all of FY25) but because three line items on that single release will tell you whether the thesis is volume-led and working-capital-healed, or merely resin-cost-pulled with inventory still stuck at 290 days. Before Q4, the April 25 Carysil 2.0 expo will either retire the credibility overhang on the domestic ₹500 Cr target or extend it by another year.

The earnings catalyst the market is already positioning for (May 15, 2026 window) is binary on working capital, not on revenue. Quant's base case puts FY27 EPS at ~₹46 on op margin of 19% and gradual US recovery — that is how the stock holds at ₹906 today; the bull case to ₹1,500+ only triggers if inventory days start unwinding from 290 and quartz utilisation confirms 80%+ on the call. The April 25 expo is softer but more narratively loaded — Historian and web research agree the ₹500 Cr domestic target has slipped at least 2 years and is now reframed by MNCL as "₹5bn over 3–4 years." If the vision document ships with concrete capacity and channel milestones (rather than another top-down number), credibility moves from 6.5 toward 8.

For / Against / My View

For

The margin recovery is printed, not promised. Three consecutive quarters at 19% operating margin with net income roughly doubling YoY. 9M FY26 NI of ₹71 Cr already clears full-year FY25 (₹64 Cr), and Q3 FY26 PAT of ₹21 Cr was +68.6% YoY. The re-rating is happening in real numbers, not forward guidance — the rare case where the street's +46% FY26 PAT forecast looks conservative against quarterly trajectory.

The sole-source relationships are now contract-bound, not aspirational. Karran's December 2024 $68M / ₹550 Cr 5-year renewal is additive to the March 2025 150,000-units/year dedicated-capacity deal that put Carysil sinks into 1,800 Lowe's US stores (supply live since May 2025). IKEA's non-US global RFQ tripled Carysil's wallet share from ~25% to ~75%, with ₹36 Cr of mould capex already committed. This is the first time in five years the bookings side of the bet is validated by external procurement, not internal revenue targets.

Working-capital latency is the cheap optionality. Inventory days at 290 have ~₹195 Cr of cash trapped vs. FY23 norms. If Q4 FY26 inventory days revert toward 200 without a revenue decline, ROCE mechanically recovers 300–400bps and FCF conversion normalises — Quant's 3-year-avg FCF path moves the P/FCF multiple from 198x to ~35x without needing a single new order. The unlock reports in 28 days.

The balance sheet was recapitalised at exactly the right moment. Historian frames the July 2024 ₹125 Cr QIP as the single most important inflection — Sherlock confirms deployment into capacity tied to a secured IKEA RFQ, not opportunistic M&A. Debt has fallen from ₹300 Cr (Mar 2024) to ₹228 Cr (Dec 2025), D/E is 0.42x, promoter dilution was from fresh issue rather than cash-out, and zero pledge runs through the entire history.

EV/EBITDA at 14x is the single clean peer-relative dislocation. Carysil's +19% FY25 revenue growth is roughly 3x what Cera or Kajaria are printing, yet EV/EBITDA sits at a clear discount to both (Cera 20.4x, Kajaria 27.1x). If 9M FY26 margins hold through Q4, institutional screeners catch up even before the utilisation story plays out.

Against

The 11-year record says this is a capex-cycle exporter, not a compounder. Quant's hardest number: ₹611 Cr of cumulative capex (FY21–FY25) produced ₹540 Cr of incremental revenue and essentially zero incremental net income — PAT flatlined at ₹53–65 Cr since FY22 even as revenue doubled. At 15.4% ROCE vs. Cera's 22.4%, paying a Cera-equivalent 28.5x P/E is paying for mean reversion that has not started and has no operational trigger date before FY27.

FCF conversion is the thesis-breaker, not a footnote. Over FY22–FY25 cumulative FCF was negative ₹29 Cr while reported PAT totalled ~₹240 Cr — roughly zero cash earnings for four years. If Q4 FY26 inventory days stay above 260 and the working-capital bloat proves structural (stale SKUs, tariff-era finished stock, permanently higher retailer stocking), the entire "margin recovery" narrative becomes an accounting artifact — Warren's 290-day inventory flag is the specific mechanism.

Customer concentration has widened, and the 18% tariff deal is fragile. The CMD disclosed in Q3 FY26 that US + IKEA together exceed 60% of quartz revenue, with Karran alone running ~20–25% of quartz volume as sole-source. The April 15, 2026 Reuters piece noted the US-India 18% framework "has been clouded by a Supreme Court ruling" — the deal was announced via social media, is not formally ratified, and any step back toward 25%+ forces Carysil to re-impose 15–20% customer-support discounts exactly as it did in H1 FY26.

Credibility is 6.5/10 because the India pivot keeps slipping. Historian logged 6 of 12 tracked promises as hits; the 4 big misses include the ₹1,000 Cr FY25 target missed by ~18%, the domestic ₹500 Cr promise quietly reframed from "medium-term" to a 5-year vision doc, Sternhagen walked back without a formal mea-culpa, and United Granite ramp 6 quarters late. The April 25, 2026 expo is the third iteration of the same top-down India playbook — believing the new number requires discounting the last two.

Governance is B with a live compliance scar. Sherlock: FY25 NSE/BSE monetary penalty for NRC composition (a basic LODR 19(1) failure), MD pay at ~14% of standalone PAT (tripped LODR Schedule V), the MD chairs his own Risk Committee, succession is publicly unaddressed, and Sonal Ambani's exit on March 31, 2026 is filed with no successor named. None of these is fatal, but they compound the "trust the founder" requirement at precisely the valuation where trust is most expensive.

My View

Close call, slight edge to the bears — but only because the price has already moved. At ₹906 the stock has doubled off the ₹582 tariff-scare low, which means you are no longer paid for the asymmetry that existed six months ago. The real tension across the four specialists is that Warren and Historian both see a genuinely cleaner operating story than the last five years (margins printed, capacity utilised, IKEA and Karran contracted), while Quant's multi-year capital-efficiency ledger and Sherlock's credibility read both argue that the business earns 15% ROCE on a Cera-equivalent multiple — expensive unless inventory unlocks and India accelerates simultaneously. I would not short this and I would not chase it here; I would wait out the April 25 expo and the May 15 Q4 print, specifically watching for inventory days to close below 250 and for management to tie the April India plan to concrete capacity commitments rather than another ₹500 Cr aspiration. The single data point that would flip the view bullish is an inventory-days print at or below 230 on the Q4 FY26 balance sheet — because that is the one number on which Warren's operational thesis, Quant's valuation math, and the base-case P/FCF all converge, and it reports before any of the harder narrative tests have to be passed.